Investigators ready early-stage trial for HIV vax; Astellas collaborates on tropical disease drugs; China faces drug-resistant TB epidemic;

@FierceBiotech: Stanford spinoff Syapse debuts cloud-based R&D software. News | Follow @FierceBiotech

@JohnCFierce: Ain't it cool: Novartis/UCSF team develop computer program to spot potential adverse side effects in experimental drugs. More | Follow @JohnCFierce

> Canadian investigators are laying the groundwork for a Phase I safety study of an experimental HIV vaccine, SAV001. "FDA approval for human clinical trials is an extremely significant milestone for our vaccine, which has the potential to save the lives of millions of people around the world by preventing HIV infection," said Dr. Chil-Yong Kang. Story

> Astellas Pharma and the Drugs for Neglected Diseases initiative announced an agreement today to collaborate on drug discovery research for three tropical diseases: leishmaniasis, Chagas disease, and sleeping sickness. Release

> Cambridge, MA-based Edimer Pharmaceuticals has won fast-track status for EDI200, the company's recombinant protein therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). Release

Pharma News

@FiercePharma: Analysts see Glaxo boosting its bid for Human Genome, but only by $1 or $2 per share--Bloomberg. Story | Follow @FiercePharma

> ADA cancer-risk data clears Sanofi's Lantus. News

> Forest Labs slashes forecast on wilting Lexapro sales. Article

> NICE does an about-face, nixing cancer nod on Xgeva. Story

> Supreme Court to put Amgen shareholders' class action on trial. News

Medical Devices News

@FierceMedDev: BSX CEO Michael Mahoney says the company plans to make a splash in the renal denervation race this year. More | Follow @FierceMedDev

> Boston Sci is joining the renal denervation race. Article

> Aurora Diagnostics pulls plug on IPO. News

> CDRH's Shuren: Device approval process is already improving. More

Biotech Research News

> Anti-rejection drug for bone marrow transplants to hit human trials by 2016. Story

> 2 HIV drugs prevent breast cancer metastasis in preclinical trials. Article

> New drug shows reduces post-stroke brain damage risk in mice. More

> Enzyme revealed to be bacteria-killing maestro after all. Item

Pharma Manufacturing News

> Siemens faces more issues with U.S. regulators.  Story

> Fresenius' Kabi unit prospering on mistakes of competitors. Article

> Lilly expands manufacturing in China with Novast deal. News

> Out of the box FDA says Perjeta faces shortage challenges. More

And Finally… China's CDC says that a new national survey proves that the country faces an epidemic of drug-resistant tuberculosis. A third of all new cases and half of all previously treated patients have proven resistant to currently used antibiotics. And about one in 10 cases are resistant to four antibiotics. Report

 

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.